サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605880

腫瘍性骨軟化症市場、規模、シェア、動向、産業分析レポート：治療タイプ別、エンドユーザー別、地域別 - 市場予測 2025年～2034年

Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Users, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
腫瘍性骨軟化症市場、規模、シェア、動向、産業分析レポート：治療タイプ別、エンドユーザー別、地域別 - 市場予測 2025年～2034年
出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、腫瘍性骨軟化症の市場規模は2034年までに1億5,300万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

腫瘍性骨軟化症（TIO）市場は、希少な骨疾患に対する認識の高まり、診断技術の進歩、リン酸塩の浪費や骨ミネラル化の問題を引き起こす様々な腫瘍に関連するTIOの有病率の上昇によって牽引されています。この市場は、標的治療薬や新規治療法の開発に関連する機会や、この疾患の効果的な管理のための研究開発への投資の増加から利益を得ています。

期待される市場動向としては、個別化医療への注目、TIOをより正確に特定し治療するための遺伝子・分子診断の活用などが挙げられます。全体として、疾患メカニズムの理解、患者の転帰の改善、治療オプションのパイプラインの拡大により、市場は成長を遂げています。

腫瘍性骨軟化症市場レポートハイライト

治療タイプ別分析では、リン酸塩の補充や標的治療を通じて病態を管理する上で重要な役割を果たすことから、薬剤およびサプリメントセグメントが腫瘍性骨軟化症市場を独占しています。しかし、手術手技の進歩や腫瘍切除への注力の高まりにより、外科手術が重要な成長分野として牽引力を増しています。

エンドユーザー別の分析では、病院がTIOの診断と治療の主要な場として市場をリードしており、包括的なケアと専門的な機器を提供しています。外来手術センターは、低侵襲手技の進歩や外来治療に対する患者の嗜好の高まりにより、急速な成長を遂げています。

北米はTIO市場において支配的な地域であるが、これは高度なヘルスケア・インフラと多額の研究投資に起因します。アジア太平洋は最も成長率の高い地域であり、ヘルスケア施設の改善、認知度の向上、患者数の増加がその要因となっています。

腫瘍性骨軟化症（TIO）市場に積極的に関与している主要企業には、Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company, Amgen Inc., Novartis AG, Sanofi S.A., Pfizer Inc., AbbVie Inc., and Horizon Therapeutics.などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 腫瘍性骨軟化症の世界市場の洞察

  • 市場スナップショット
  • 腫瘍性骨軟化症の市場力学
    • 促進要因と機会
      • 標的療法への注目が高まる
      • 希少疾患に対する認識と診断の向上
    • 抑制要因と課題
      • 高額な治療費
  • PESTEL分析
  • 腫瘍性骨軟化症市場のアプリケーション動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 腫瘍性骨軟化症の世界市場：治療タイプ別

  • 主な調査結果
  • イントロダクション
  • 医薬品とサプリメント
  • 手術

第6章 世界の腫瘍性骨軟化症市場：エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院
  • 外来手術センター
  • 専門クリニック
  • その他

第7章 世界の腫瘍性骨軟化症市場：地域別

  • 主な調査結果
  • イントロダクション
    • 腫瘍性骨軟化症市場評価：地域、2020～2034年
  • 北米
    • 北米：治療タイプ別、2020年～2034年
    • 北米：エンドユーザー別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療タイプ別、2020～2034年
    • 欧州：エンドユーザー別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療タイプ別、2020年～2034年
    • アジア太平洋地域：エンドユーザー別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療タイプ別、2020～2034年
    • 中東・アフリカ：エンドユーザー別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療タイプ別、2020～2034年
    • ラテンアメリカ：エンドユーザー別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Ultragenyx Pharmaceutical Inc.
  • Kyowa Kirin Co., Ltd.
  • Eli Lilly and Company
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • Pfizer Inc.
  • AbbVie Inc.
  • Horizon Therapeutics
図表

List of Tables:

  • Table 1 Global Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 2 Global Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 3 North America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 4 North America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 5 U.S.: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 6 U.S.: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 7 Canada: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 8 Canada: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 9 Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 10 Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 11 UK: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 12 UK: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 13 France: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 14 France: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 15 Germany: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 16 Germany: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 17 Italy: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 18 Italy: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 19 Spain: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 20 Spain: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 21 Netherlands: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 22 Netherlands: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 23 Russia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 24 Russia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 25 Rest of Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 26 Rest of Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 27 Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 28 Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 29 China: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 30 China: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 31 India: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 32 India: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 33 Malaysia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 34 Malaysia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 35 Japan: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 36 Japan: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 37 Indonesia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 38 Indonesia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 39 South Korea: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 40 South Korea: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 41 Australia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 42 Australia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 43 Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 44 Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 45 Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 46 Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 47 Saudi Arabia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 48 Saudi Arabia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 49 UAE: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 50 UAE: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 51 Israel: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 52 Israel: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 53 South Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 54 South Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 55 Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 56 Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 57 Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 58 Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 59 Mexico: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 60 Mexico: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 61 Brazil: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 62 Brazil: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 63 Argentina: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 64 Argentina: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • Table 65 Rest of Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • Table 66 Rest of Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • List of Figures:
  • Figure 1. Global Tumor-Induced Osteomalacia Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Tumor-Induced Osteomalacia Market, by Treatment Type, 2024 & 2034 (USD Million)
  • Figure 8. Market by End User
  • Figure 9. Global Tumor-Induced Osteomalacia Market, by End User, 2024 & 2034 (USD Million)
目次
Product Code: PM5232

The tumor-induced osteomalacia market size is expected to reach USD 153.00 million by 2034, according to a new study by Polaris Market Research. The report "Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Drugs & Supplements and Surgery), End Users (Hospitals, Ambulatory Surgery Centers, Speciality Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America and the Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The tumor-induced osteomalacia (TIO) market is driven by increasing awareness of rare bone disorders, advancements in diagnostic techniques, and the rising prevalence of TIO, which is linked to various tumours causing phosphate wasting and bone mineralisation issues. The market benefits from opportunities related to the development of targeted therapies and novel treatments, as well as the growing investment in research for effective management of the condition.

Expected market trends include a focus on personalised medicine and the utilisation of genetic and molecular diagnostics to identify and treat TIO more accurately. Overall, the market is experiencing growth due to enhanced understanding of the disease mechanisms, improving patient outcomes, and the expanding pipeline of therapeutic options.

Tumor-Induced Osteomalacia Market Report Highlights

By treatment type analysis, the drugs and supplements segment dominates the tumor-induced osteomalacia market due to their crucial role in managing the condition through phosphate replacement and targeted therapies. However, surgery is gaining traction as a significant growth area with advancements in surgical techniques and increased focus on tumour resection.

By end users analysis, the hospitals lead the market as the primary setting for TIO diagnosis and treatment, offering comprehensive care and specialised equipment. Ambulatory surgery centers are experiencing rapid growth, driven by advancements in minimally invasive procedures and increasing patient preference for outpatient care.

North America is the dominant region in the TIO market, attributed to advanced healthcare infrastructure and significant research investments. Asia Pacific is the highest-growing region, driven by improving healthcare facilities, increasing awareness, and a growing patient population.

Key players actively involved in the tumor-induced osteomalacia (TIO) market include Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company, Amgen Inc., Novartis AG, Sanofi S.A., Pfizer Inc., AbbVie Inc., and Horizon Therapeutics.

Polaris market research has segmented the tumor-induced osteomalacia market report based on treatment type, end users, and region:

By Treatment Type Outlook (Revenue - USD Million, 2020-2034)

  • Drugs & Supplements
  • Surgery

By End Users Outlook (Revenue - USD Million, 2020-2034)

  • Hospitals
  • Ambulatory Surgery Centers
  • Speciality Clinics
  • Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of the Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Tumor-Induced Osteomalacia Market Insights

  • 4.1. Tumor-Induced Osteomalacia Market - Market Snapshot
  • 4.2. Tumor-Induced Osteomalacia Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Focus on Targeted Therapies
      • 4.2.1.2. Rising Awareness and Diagnosis of Rare Diseases
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Tumor-Induced Osteomalacia Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Tumor-Induced Osteomalacia Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  • 5.3. Drugs & Supplements
    • 5.3.1. Global Tumor-Induced Osteomalacia Market, by Drugs & Supplements, by Region, 2020-2034 (USD Million)
  • 5.4. Surgery
    • 5.4.1. Global Tumor-Induced Osteomalacia Market, Surgery, by Region, 2020-2034 (USD Million)

6. Global Tumor-Induced Osteomalacia Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Global Tumor-Induced Osteomalacia Market, by Hospitals, by Region, 2020-2034 (USD Million)
  • 6.4. Ambulatory Surgery Centers
    • 6.4.1. Global Tumor-Induced Osteomalacia Market, by Ambulatory Surgery Centers, by Region, 2020-2034 (USD Million)
  • 6.5. Speciality Clinics
    • 6.5.1. Global Tumor-Induced Osteomalacia Market, by Speciality Clinics, by Region, 2020-2034 (USD Million)
  • 6.6. Others
    • 6.6.1. Global Tumor-Induced Osteomalacia Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Tumor-Induced Osteomalacia Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Tumor-Induced Osteomalacia Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Tumor-Induced Osteomalacia Market - North America
    • 7.3.1. North America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.3.2. North America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.3.3. Tumor-Induced Osteomalacia Market - U.S.
      • 7.3.3.1. U.S.: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.3.2. U.S.: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.3.4. Tumor-Induced Osteomalacia Market - Canada
      • 7.3.4.1. Canada: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • 7.4. Tumor-Induced Osteomalacia Market - Europe
    • 7.4.1. Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.4.2. Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.3. Tumor-Induced Osteomalacia Market - UK
      • 7.4.3.1. UK: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.4. Tumor-Induced Osteomalacia Market - France
      • 7.4.4.1. France: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.4.2. France: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.5. Tumor-Induced Osteomalacia Market - Germany
      • 7.4.5.1. Germany: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.6. Tumor-Induced Osteomalacia Market - Italy
      • 7.4.6.1. Italy: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.7. Tumor-Induced Osteomalacia Market - Spain
      • 7.4.7.1. Spain: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.8. Tumor-Induced Osteomalacia Market - Netherlands
      • 7.4.8.1. Netherlands: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.9. Tumor-Induced Osteomalacia Market - Russia
      • 7.4.9.1. Russia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.4.10. Tumor-Induced Osteomalacia Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • 7.5. Tumor-Induced Osteomalacia Market - Asia Pacific
    • 7.5.1. Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.3. Tumor-Induced Osteomalacia Market - China
      • 7.5.3.1. China: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.3.2. China: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.4. Tumor-Induced Osteomalacia Market - India
      • 7.5.4.1. India: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.4.2. India: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.5. Tumor-Induced Osteomalacia Market - Malaysia
      • 7.5.5.1. Malaysia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.6. Tumor-Induced Osteomalacia Market - Japan
      • 7.5.6.1. Japan: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.7. Tumor-Induced Osteomalacia Market - Indonesia
      • 7.5.7.1. Indonesia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.8. Tumor-Induced Osteomalacia Market - South Korea
      • 7.5.8.1. South Korea: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.9. Tumor-Induced Osteomalacia Market - Australia
      • 7.5.9.1. Australia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.5.10. Tumor-Induced Osteomalacia Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • 7.6. Tumor-Induced Osteomalacia Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.6.3. Tumor-Induced Osteomalacia Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.6.4. Tumor-Induced Osteomalacia Market - UAE
      • 7.6.4.1. UAE: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.6.5. Tumor-Induced Osteomalacia Market - Israel
      • 7.6.5.1. Israel: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.6.6. Tumor-Induced Osteomalacia Market - South Africa
      • 7.6.6.1. South Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.6.7. Tumor-Induced Osteomalacia Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
  • 7.7. Tumor-Induced Osteomalacia Market - Latin America
    • 7.7.1. Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.7.3. Tumor-Induced Osteomalacia Market - Mexico
      • 7.7.3.1. Mexico: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.7.4. Tumor-Induced Osteomalacia Market - Brazil
      • 7.7.4.1. Brazil: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.7.5. Tumor-Induced Osteomalacia Market - Argentina
      • 7.7.5.1. Argentina: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
    • 7.7.6. Tumor-Induced Osteomalacia Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Ultragenyx Pharmaceutical Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Kyowa Kirin Co., Ltd.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Eli Lilly and Company
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Amgen Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Novartis AG
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi S.A.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. AbbVie Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Horizon Therapeutics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development